Functional and structural impact of pirfenidone on the alterations of cardiac disease and diabetes mellitus

• The compound pirfenidone (PDF) is well known for its ability to inhibit fibrosis.
• It produces beneficial effects in several diseases as those linked to diabetes.
• Apart from inhibiting fibrosis, other mechanisms could also underlie PFD effects.
• That is the case for chronic stimulation of cardiac L-type Ca channels.
• This action may contribute to explaining both antiarrhythmic effects and enhanced contractility.

A synthetic compound, termed pirfenidone (PFD), is considered promising for the treatment of cardiac disease. It leads to beneficial effects in animal models of diabetes mellitus (DM); as well as in heart attack, atrial fibrillation, muscular dystrophy, and diabetic cardiomyopathy (DC). The latter is a result of alterations linked to metabolic syndrome as they promote cardiac hypertrophy, fibrosis and contractile dysfunction. Although reduced level of fibrosis and stiffness represent an essential step in the mechanism of PFD action, a wide range of functional effects might also contribute to the therapeutic benefits. For example, PFD stimulates L-type voltage-gated Ca2+ channels (LTCCs), which are pivotal for a process known as excitation–contraction coupling (ECC). Recent evidence suggests that these two types of actions – namely structural and functional – aid in treating both cardiac disease and DM. This view is supported by the fact that in DC, for example, systolic dysfunction arises from both cardiac stiffness linked to fibrosis and down-regulation of ECC. Thus, not surprisingly, clinical trials have been conducted with PFD in the settings of DM, for treating not only cardiac but also renal disease. This review presents all these concepts, along with the possible mechanisms and pathophysiological consequences.

Figure optionsDownload as PowerPoint slide